Neoplastic development in plasma cells
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: An increasing number of model systems of plasma cell tumor (PCT) formation have been and are being developed. Discussed here are six models in mice and multiple myeloma (MM) in humans. Each model illustrates a unique set of biological factors. There are two general types of model systems: those that depend upon naturally arising mutagenic changes (pristane‐induced PCTs, 5TMM, and MM) and those that are associated with oncogenes (Eµ‐v‐abl), growth factors [interleukin‐6 (IL‐6)], and anti‐apoptotic factors (Bcl‐x L/Bcl‐2). PCTs develop in several special tissue microenvironments that provide essential cytokines (IL‐6) and cell–cell interactions. In mice, the activation and deregulation of c‐myc by chromosomal translocations is a major feature in many of the models. This mechanism is much less a factor in MM and the 5T model in mice. Genetically determined susceptibility is involved in many of the mouse models, but only a few genes have been implicated thus far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213 · cited 2×
“5-kb Bcl2 minigene, specifically the complete Bcl-2-coding sequence and J6-E8-Cg1 (84).”
BackgroundInfluentialIgG1 plasmacytosis in interleukin 6 transgenic mice
Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7547 · Cited by 586 · cited 3×
“Over and/or deregulated expression of IL-6 in the H-2L-hu-IL-6 Tg causes progressive accumulations of plasma cells in lymphoid tissues (plasma cell hyperplasia) and hypergammaglobulinemia (72, 73)”
BackgroundGiuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Suematsu, S., Matsusaka, T., Matsuda, T., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.232 · Cited by 227 · cited 5×
“These C57BL/6-H2L-hu-IL6 Tg mice (IL-6Tg) also developed the lymphadenopathy, hypergammaglobulinemia, and splenomegaly but also were able to breed successfully (73).”
BackgroundInfluentialRANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.
Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125 · cited 3×
“Roux S, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma.”
BackgroundImmunocytochemistry reveals RANKL expression of myeloma cells
Sezer, O., Heider, U., Jakob, C., Zavrski, I., Eucker, J., Possinger, K., Sers, C., & Krenn, V. (2002) · Blood · doi:10.1182/blood-2002-01-0148 · Cited by 110
Human bone marrow myeloma cells express RANKL.
Sezer, O., Heider, U., Jakob, C., Eucker, J., Possinger, K., & Roodman, G. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.353 · Cited by 104
Cited by
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/IgH Translocations
Robbiani, D. F., Bothmer, A., Callen, E., Reina-San-Martin, B., Dorsett, Y., Difilippantonio, S., Bolland, D. J., Chen, H. T., Corcoran, A. E., Nussenzweig, A., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.062 · Cited by 467
AID Is Required for c-myc/IgH Chromosome Translocations In Vivo
Ramiro, A. R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., Honjo, T., Nussenzweig, A., & Nussenzweig, M. C. (2004) · Cell · doi:10.1016/j.cell.2004.08.006 · Cited by 465
MicroRNA-155 Suppresses Activation-Induced Cytidine Deaminase-Mediated Myc-Igh Translocation
Dorsett, Y., McBride, K. M., Jankovic, M., Gazumyan, A., Thai, T.-H., Robbiani, D. F., Di Virgilio, M., San-Martin, B. R., Heidkamp, G., Schwickert, T. A., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.002 · Cited by 458
Myc Dynamically and Preferentially Relocates to a Transcription Factory Occupied by Igh
Osborne, C. S., Chakalova, L., Mitchell, J. A., Horton, A., Wood, A. L., Bolland, D. J., Corcoran, A. E., & Fraser, P. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050192 · Cited by 394
Metadata
- Authors
- Potter, M.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2003-07-07
- Volume
- 194
- Issue
- 1
- Pages
- 177-195
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2068927904
- Cited by
- 123
- References
- 8
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoplastic development in plasma cells. https://app.cochat.ai/papers/10.1034/j.1600-065x.2003.00061.x
- The paper
- Potter, M. (2003). Neoplastic development in plasma cells. Immunological Reviews. https://doi.org/10.1034/j.1600-065x.2003.00061.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.